Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;14(8):1075-1086.
doi: 10.1016/j.jiph.2021.06.013. Epub 2021 Jun 27.

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Mohd Imran  1 , Ahmed Subeh Alshrari  2 , Syed Mohammed Basheeruddin Asdaq  3 , Abida  4
Affiliations
Review

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Mohd Imran et al. J Infect Public Health. 2021 Aug.

Abstract

The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009. This patent review summarizes the remdesivir based inventions to treat/prevent COVID-19 and other disorders from 2009 to May 16, 2021, emphasizing the patents related to medical and pharmaceutical sciences. The primary patents/patent applications of remdesivir are related to its compositions, new combinations with other therapeutic agents, delivery systems, and new indications. The inventive combinations have displayed synergistic effects against COVID-19, whereas the delivery systems/compositions have improved patient compliance. The inventions related to new indications of remdesivir to treat Ebola, hepatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and cardiovascular complications enhance its therapeutic area. Many new innovative combinations and delivery systems of remdesivir are anticipated to provide better treatment for COVID-19.

Keywords: COVID-19; Combination; Composition; Delivery system; New indication; Patent; Remdesivir.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Remdesivir (GS-5734).
Scheme 1
Scheme 1
Life cycle of SARS-CoV-2 in host cell and mechanism of action of remdesivir.
Fig. 2
Fig. 2
Remdesivir triphosphate (GS-443902).
Fig. 3
Fig. 3
GS-704277.
Fig. 4
Fig. 4
GS-441524-MP.
Fig. 5
Fig. 5
GS-441524.
Scheme 2
Scheme 2
The intracellular metabolic pathway of remdesivir.
Scheme 3
Scheme 3
Methodology of the patent literature search.
See this image and copyright information in PMC

References

    1. Kumar A., Singh R., Kaur J., Pandey S., Sharma V., Thakur L., et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol. 2021;11 doi: 10.3389/fcimb.2021.596201. - DOI - PMC - PubMed
    1. World Health Organization . 2021. WHO coronavirus (COVID-19) dashboard.https://covid19.who.int/ [Accessed 16 May 2021]
    1. World Health Organization . 2021. Coronavirus disease (COVID-19) pandemic.https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed 16 May 2021]
    1. Fricke-Galindo I., Falfán-Valencia R. Pharmacogenetics approach for the improvement of COVID-19 treatment. Viruses. 2021;13(3):413. doi: 10.3390/v13030413. - DOI - PMC - PubMed
    1. Lamberghini F., Testai F.D. COVID-2019 fundamentals. J Am Dent Assoc. 2021;152(5):354–363. doi: 10.1016/j.adaj.2021.01.014. - DOI - PMC - PubMed